Postmarket JUPITER Registry Evaluates Second-Generation JenaValve to Treat Aortic Regurgitation
December 8, 2017—One-year outcomes from the postmarket JUPITER registry evaluating the safety and efficacy of transapical aortic valve implantation using the second-generation JenaValve transcatheter heart valve (JenaValve Technology GmbH) for aortic regurgitation were published by Miriam Silaschi, MD, et al online ahead of print in Catheterization and Cardiovascular Interventions (CCI).
According to the investigators, JenaValve is designed to overcome technical challenges seen in aortic regurgitation patients through a leaflet clipping mechanism.
The registry enrolled 30 patients with aortic regurgitation from 2012 to 2015. The mean patient age was 74.4 ± 9.3 years. Procedural success was 96.7% (29/30). One patient was converted to open surgery, and no annular ruptures or coronary ostia obstructions occurred.
In CCI, the investigators reported that mortality at 30 days was 10% (3/30). The combined safety endpoint was met in 13.3% (4/30). Paravalvular regurgitation was not present/trivial in 84.6% (22/26) and mild in 15.4% (4/26). The rate of permanent pacemaker implantation was 3.8% (1/26). The 1-year Kaplan-Meier survival rate was 79.9%, and the 1-year combined efficacy rate was 73.1% (19/30). No further strokes were observed during 1 year of follow-up.
This multicenter registry demonstrated satisfactory outcomes using the JenaValve device for predominant aortic regurgitation, with low rates of transcatheter heart valve embolization, residual aortic regurgitation, and permanent pacemaker implantation. The results using JenaValve for aortic regurgitation encourage its use for this indication, concluded the investigators in CCI.
advertisement
Featured Video
Evolut™ PRO System
Sponsored by Medtronic
Related Articles
Current Status and Expectations for Low-Risk TAVI Trials
An expert opinion on how current clinical trials will impact the future of TAVI procedures in low-risk patients.
With Marc Dweck, MD, PhD
East Meets West: Emerging Transcatheter Aortic Valve Technologies
Emerging valve systems and iterative technologies from around the world and how they could shape global practice going forward.
By Federico Mercanti, MD; Zhen-Gang Zhao, MD; Antoinette Neylon, MD, BCh; Mao Chen, MD, PhD; and Darren Mylotte, MD, BCh
Top 5 Articles From October 2017
Prevention of Radial Artery Occlusion After Transradial Catheterization
Factors influencing radial artery occlusion and different methods for its prevention.
By Amir Solomonica, MD; and Shahar Lavi, MD
Robotic PCI Technologies
Remote control PCI benefits patients and interventional cardiologists.
By Giora Weisz, MD, FACC, FESC, FSCAI
Compartment Syndrome After Radial Artery Catheterization
A review of the literature.
By Samer Mowakeaa, MD; and Robert S. Dieter, MD, RVT
Ulnar Access for Catheterization and Intervention
When and how radial operators should consider transulnar access as an alternative to transfemoral access.
By Safi U. Khan, MD; Michael DePersis, DO; and Edo Kaluski, MD, FACC, FESC, FSCAI
An Anesthesiologist’s Perspective of Radial Artery Catheterization
A brief summary of radial artery catheterization and the factors an anesthesiologist considers before and during placement, with an emphasis on ultrasound guidance.
By Todd Novak, MD; and Luke Janik, MD
Top 5 from EVToday's Current Issue
Endovascular Treatment of Pelvic Congestion Syndrome
PCS remains underdiagnosed and undertreated, but recognizing this condition and providing endovascular treatment can benefit women with chronic pelvic pain.
By Andrew C. Picel, MD; and Anne C. Roberts, MD
A US Perspective: PAE: Is It Ready for Prime Time?
A commentary on the benefits of prostatic artery embolization, opportunities for training, and challenges to widespread adoption.
By Sandeep Bagla, MD
Splenic Artery Embolization: Proximal or Distal?
A review of when proximal or distal embolization should be used, optimal technique, and results of studies evaluating outcomes.
